contact cowen salesperson detail
call open media
host
recoveri tavr tmvr
contact cowen salesperson detail
call open media
host
medic director structur heart diseas intermountain heart institut adjunct
associ professor medicin univers utah school medicin
surgic director structur heart program mount sinai health system
associ professor medicin icahn school medicin mount sinai
call frack go us
pleas see addendum report import disclosur
contact cowen salesperson detail
call open media
host
greg sommer head merger acquisit intrepid financi partner
david deckelbaum oil ga explor product analyst cowen
gabe daoud oil ga explor product analyst cowen
contact cowen salesperson detail
call open media
host
andi bechtolsheim co-found chairman chief develop offic arista
jayshre ullal ceo arista
report nuplazid sale meet consensu
decreas sale guidanc due anticip covid-rel disrupt
nrx next major catalyst key focu investor snda file drp
still expect potenti approv also explor
combin mdd studi potenti data
link full note
last weekli period nielsen data shown consist yoy revenu
growth hard seltzer becom clear consum adopt categori
especi amid environ revisit industri data consum survey
data scenario analysi reiter outperform rate rais
pt
link full note
investor quick sour smartphon suppli chain
execut except well sinc last octob benefit
broad-bas uplift content across handset network infrastructur
cours healthi exposur gan deploy enabl long tail
margin growth enhanc top pick
link full note
eat surg partial offset ride nt declin po ebitda focu
report solid result beat gb adj net aid rise take
rate ebitda loss slightli higher march ride declin sharp
biz apr grown week row sinc trough eat biz
acceler amid pandem surg commit po ebitda larg
cost cut tweak estimate maintain outperform pt
link full note
ct gov analysi continu show modest trial disrupt neg signal
acceler past week total trial decreas recruit trial
decreas vs last week primarili non-oncolog indic trial
primari complet decreas suspend trial increas
march april trial start slightli lag averag
link full note
gocovri revenu reach in-lin although experienc
gener favor momentum expect newer launch product
unfortun impact new patient start believ prove
temporari paus manag take thought step minim
impact continu improv could becom construct
link full note
given limit gross margin upsid meaning improv ep cash flow
appear depend upon revenu growth result outlook suggest stabil
importantli cite three new tier win potenti
sizabl given spotti histori remain cautiou ultim impact revenu
even ep maintain market perform
link full note
consum end market soft overshadow progress auto/
enterpris market drive posit momentum time
share net cash nearli half market cap signific dri powder
tuck-in capit return augment design pipelin maintain outperform
link full note
report financi pipelin updat data timelin
maintain despit pandem pivot top-line data pfic
trial odevixibat due mid nda file soon data
elobixibat trial nash/nafld also expect new biliari atresia
trial underway alagil initi
link full note
result miss across oper metric due withdrew
guidanc despit underwhelm result think cost reduct action
alreadi taken improv outlook management expect bp adj
ebitda margin improv respect find strong book
encourag convert book revenue key improv sentiment
link full note
report big beat despit pullfoward due neglig
impact adj op incom think indic strength underli
busi advers impact management expect busi
rebound april trend encourag think could see strong growth
due pent-up demand pharma mwi
link full note
amtech navig crisi well plenti cash cushion
see mutli-quart paus mid high teen revenu run rate amtech back
end power semi sic/l equip usual lag spend cycl manag
note posit lt secular trend plenti cash
current market cap
link full note
caution longer sale head guidanc pull
report good w/ cloud sub growth estimate cloud
sub guid growth slightli estimate ps licens expect see
increment pressur guid withdrawn exposur impact vertic
smb low management note longer sale cycl tougher net add valuat remain
rich sale ah maintain market perform pt
link full note
ardx updat notabl in-lin financials/expens confirm
plan submit nda tenapanor hyperphosphatemia mid-year aim
approval/launch announc trial start
catalyst could includ data phreedom amplifi
normal well announc partner ibs-c
link full note
mix tough environ result pull guidanc
asur report mix rev slightli street weaker book
withdrew guidanc given smb exposur expect meaning near-
term pressur custom churn furlough worker ppp make way
expect improv shutdown get lift asur take cost-cut
action preserv ebitda maintain outperform pt
link full note
atla near-term focu busi move aircraft capit
current high yield environ benefit increas number
dedic aircraft probabl opportunist buyer convert
passeng aircraft given declin valuat militari busi slow due
govern restrict expect return june
link full note
report today pipelin updat due trial site closur
dose paus across trial data timelin maintain
howev gaucher dose data updat fabri cystinosi
pomp program asgct may see recent saladex deal
drive futur valu across whole platform
link full note
report better top-lin ep result revis street estim
pull guidanc due uncertainti surround outlin
preliminari impact april hit partial off-set
benefit associ outlook view impact moder
rel peer
link full note
line preview slightli better past coupl wk domest
travel market china korea vietnam germani part us ad cost
line biz non-ad cut plan estimate burn get
environ break-even best capit space yr runway reit
outperform pt long trek back level
link full note
adjust beat consensu number stronger fuel margin
compani see liquid need worst-cas event
line current liquid estim break-even remaind
year near-term specialti outlook remain less clear manag cite pressur
volum margin maintain market perform pt
link full note
canadian cannabi earn kick see opportun upsid
adult use sale pantri load end march howev variou put
take like limit overal compani growth phase cost-cut
initi like weight continu broadli prefer cannabi
canadian cannabi within coverag
link full note
adj ebitda share target price repres highli lever
invest return somewhat normal advertis industri spend
reason assumpt within rebound out-of-hom continu take
share tradit media
link full note
improv commerci perform derail near-term due
maze attack see like trough stop short
quantifi outlook cloud near-term potenti mute expect
print discount valuat support downsid lack visibl catalyst
extend turnaround keep us sidelin pt
link full note
udenyca sale reach in-lin pre-announc although
pandem like caus q/q lower sale prove transient
manag anticip recoveri patient normal like importantli
udenyca share appear competit dynam
impact anticip current run-rat persist
link full note
top pick definit artifici constrain demand coil
spring fabtech navig weak macro better peer med-tech
recov quickli procedur allow management move swiftli address cost nt
coven concern effect navig worst possibl macro given market
provid confid abil leverag turn
link full note
better expect top-lin perform overshadow addit
challeng turnaround offset factor via increas
govern activ though profit pressur high-margin busi
impact hsa/transport posit traction new busi book allevi
downsid pressur share like stay rang bound near-term pt
link full note
strong partnership cash-flow least expect astella
upcom present
materi data catalyst end cash
fund believ strong cash balanc posit well advanc
program environ
link full note
result better expect certain biopharma/dx busi remain
resili core revenu growth guidanc least good better
expect view believ remain well posit weather
pandem given attract busi portfolio strong manag
link full note
see market alreadi bottom necessarili improv
yet result solid earli sign capac exit market
solid financi foot term loan due plan
strateg divest aveda improv margin lessen exposur
soft energi market reit outperform pt
link full note
drna driven slightli higher opex vs previous
announc delay clinic timelin push near-term catalyst
slightli highli anticip hbv data interim multidos data
day earli august offer next key driver stock recent collabor provid
solid cash runway partner begun select target
link full note
report messi result provid downsid core-ffo/shr guidanc
although book highest compani includ inxn
achiev core-ffo/shr growth estim need achiev
average thru lastli stock trade updat affo/shr
repres record high find less attract
link full note
solid ebitda/fcf management remain confid fund
report upsid rev/ebitda result still prove gener good
enough focu wireless build management provid mani insight remain
highli confid buildout partnership fund admittedli mani
unknown still view concept stock management align loyalti
sharehold extract optim valu lucr spectrum
link full note
revis better fear still mute earn recap
u/p miss poor cash flow revis appear less
sever initi fear addit cost-cut mix less
disrupt drive improv could run-rat
consensu favor set revis continu see stock
link full note
report heplisav revenue vs consensu
previous remov heplisav guidanc note vaccin
util began declin march due covid compani sign sever
vaccin collabor expect least one candid enter clinic
year continu believ under-valued heplisav
link full note
esta deliv guidanc plan navig challeng condit
face headwind esta post revenu high end
guidanc rang although bring continu challeng compani
alreadi see augment procedur return albeit limit capac sever
geographi encourag earli sign recoveri remain firm
believ attract long-term growth prospect motiva
link full note
revenue better consensu adj ebitda
better remain posit given minim disrupt
enabl compani continu track toward year-end profit new
partnership target think current guidanc could prove conserv
contempl potenti impact higher medicaid enrol
link full note
forward guidanc end-market perspect perform market
compar favor vs peer healthcar semi demand expand
industrial/muni pressur mute process natur busi
howev share give us paus even attract
valu ev/ebitda given higher leverag
link full note
reconcil fulfil issu leav demand recoveri time overhang
near-term demand impact pronounc expect partial off-set
stronger profit cost action forecast stage improv
recoveri total compani growth make stride mitig
suppli constraint capac believ share fairli valu amid heighten
link full note
roxadustat post in-line vs cowen launch china good
start esp consid impact jan feb expect sale
china see meaning ramp given achiev hospit access
nrdl list next meaning catalyst akebia vadadustat competit data
pre-dialysis follow roxadustat approv
link full note
unclear project sale time lead guidanc pull transit go
due potenti delay financing/transact close larg project previous
anticip sale manag pull guidanc year move
base seri transit issu appear go well core
long-term posit view share seri util rate higher
watt yield arc rate continu improv
link full note
host bullish earn call compani commun solid
path achiev doubl digit adj ep growth despit relat revenu
pressur pace expens synergi acceler flexibl deliv
see strategi chang long-term ceo yabuki retir remain
link full note
report robust result beat our/consensu estim top
bottom line april revenu trend y/i ahead initi
expect appear bottom believ superior posit
peer come flexibl pursu charg growth
valuat reset lower
link full note
report adj ep us consensu look stale book
declin less model sale vs dd assumpt margin
disappoint energi lever firm midst meltdown
market perhap shock investor given mani pass season though
histor reward absent clear beat
link full note
glu report signific book upsid rais top bottom line guidanc
fy compani aggress take advantag disrupt on-line
advertis market acquir new user glu appear regain signific
momentum maintain outperform rate rais pt
link full note
gritston report financi includ net loss cash balanc
updat phase data granit slate immunotherpi
program share mid-year investor webcast phase ii expans
cohort expect open continu view gritston leader
neoantigen vaccin remain outperform
link full note
recent top-lin momentum encourag though walk tight rope
continu expect run elev revenu cost social
distanc backdrop pleas recent week top-lin acceler
fear well-known risk around fee cap legisl fragil state smb macro
deterior present risk adj ebitda maintain market perform
adj ebitda price target
link full note
gh revenu robustli beat expect via stronger expect clinic volum
higher asp oper perform solid
headwind like pronounc quarterli updat
emblemat attract resili gh platform maintain
outperform rate increas price target
link full note
portfolio pipelin remain insul impact
result match pre-announce manag reiter ep
expect pipelin essenti market remain
open strong neg impact perform
current portfolio manag eas investor concern provid addit
insight resi solar exposur investor confid like boost
link full note
report result came revenu estim in-lin
adj ebitda estim due uncertainti around acquisit activ
hold outlook remain withdrawn expect result advers
impact believ model expect weak appropri
link full note
beat consensu revenue/ebitda slightli s/h letter offer mostli
posit monthli trend data april management continu prepar
spin ahead sharehold meet focus key growth vector includ
angi vimeo dotdash etc maintain outperform part
deriv price goe vs prior
link full note
result solid busi model resili growth
horizon delay expect see limit near-term catalyst
continu view core long term hold near term out-performance
could challeng p-t dcf sale
link full note
jetblu seen modest uptick demand may noth would classifi
recoveri near-term continu look solidifi cash posit
limit cash burn manag like other expect vfr leisur lead
recoveri busi struggl compani look becom effici
link full note
report net loss cash march
expect cash fund oper ph ii mission marina
presidio trial continu though covid may impact timelin present add
sle ph ib data end ind candid target protein
secret oncolog expect remain outperform
link full note
live nation report result consist pre-announce refund
trend signal posit consum demand concert side event
ban oper cash burn reduc per month continu
believ live nation liquid suffici
link full note
microchip earn call took cautiou tone peer manag
reluct call june bottom given limit visibl demand recoveri
opex cut lean inventori posit compani well rebound howev
higher leverag peer see risk/reward balanc limit visibl
link full note
announc preliminari mo mo sitravatinib nivolumab ph
nsclc cohort similar enrol criteria pivot trial compar favor
month histor benchmark docetaxel control pivot
enrol track complet combin ramp model updat
reflect advanc pipelin dcf outperform
link full note
report ep cent ahead consensu
larg unaffect show mark shift local currenc sale
roughli april though manag note sequenti
improv key market believ recoveri global energi drink demand
gradual path maintain market perform
link full note
products/servic revenu consist pre-announc revenu
growth primarili driven strong geomx instrument demand ncounter
busi neg impact revenu guidanc provid
signific y/i declin seem like long-term recov
headwind would remain sidelin due valuat
link full note
modest beat earlier expect synergi realiz leav less
realiz drive consider downward revis estim
time clear expect remain posit rest year
ebitda estim move significantli lower lower capital-expenditure assumpt temper
link full note
xhanc revenu although modestli due end
quarter pandem impact good momentum believ bode well
anticip recoveri y/i solid retention/refil
rate reflect xhanc compel efficaci improv coverag believ
momentum return continu like risk/reward level
link full note
orchard report opex line est announc strateg
realign commerci scientif prioriti new invest focu high
valu preval indic mld mp depriorit ada-scid tdt
like delay pend fda discuss new pt
link full note
ovid report today corpor updat new top-line data
rocket trial lead compound fragil fx demonstr stat
sig efficaci dose-respons opaqu top-line data pivot
neptun trial angelman expect delay due
elektra open-label endymion trial data expect
link full note
first take pluse minus eye
bit messi liquid miss street in-lin cowen higher capital-expenditure
ebitda miss asset level anadarko oil/condi miss cowen
permian modest updat program larg meet cowen
initi keep flat estim capit hold oil condi flat
screen wors capit effici perspect
link full note
first take bit messi intact
saw pluse minus oil miss street del culprit cowen
though capital-expenditure beat street cfp spot street re-affirmed
budget offici put print volum guid fy basi oil sit modest
street impli oil exit see tabl
link full note
revenu significantli ep
also due account chang fair valu adjust associ
pdl dissolut pdl monet current asset return proce
sharehold process expect complet dcf analysi suggest
pdl share fairli valu remain market perform
link full note
exceed revenu forecast view outlook year remain
larg unchang continu forecast pronounc near-term
pressur due expect manag continu invest growth
initi sign momentum build biopharma account
link full note
impact minim deem essenti busi
import posit food retail logist manag re-affirmed
guid gross bill announc potenti acquisit
unit hydrogen electrolyz compani extend size matur
gener capit loan lower cost capit
link full note
reiter outperform first-quart progress advanc launch tulsa-pro
sale better expect prof priorit imag center
lead urolog practic hospit deal compani also continu
make reimburs progress though may pose near-term challeng
think tulsa-pro gener solid demand cash-pay patient come
quarter well ahead long-term inflect help reimburs
link full note
result solid despit q/q declin contract durat deal
get defer end march management lower rev/adj guid
pressur net new biz retent rate contract durat due
cost-cut effort expect preserv profit lower estimate continu
believ oper posit strength
link full note
puma tone execut line nike peer
confid ep recoveri prior earn
rais price target ep america recoveri like
lag apac emea recoveri
link full note
flow tank given headwind start recov
leverag rebound like stock support dividend
yield solid liquid could respond sign air travel bottom
link full note
revanc enter commerci stage differenti asset via daxi
partner dermal filler importantli although dermal filler launch
delay still provid nice window commerci groundwork/
infrastructur ahead late fall approv daxi continu believ
new manag strongli differenti stori
link full note
indic shopper spend less fashion take backseat function
 frugal rvlv high custom satisfact shopper go on-line
posit solid balanc sheet histori profit rel variabl cost
structur long-term posit underpin outperform
link full note
report focu remain initi new zuranolon
trial rrt episod mdd still plan start data
expect top-line data dose shorelin still expect
expect forward zulresso revenu minim due
headwind recent restructur allow cash stretch
link full note
mcrb updat notabl optimist tone manag
highlight upcom top-lin readout potenti registration-suffici
ecospor trial recurr difficil infect track
mid-year may investor event ahead result announc logic
present trial timelin headwind asset
link full note
see block hour product declin like remain
depress smaller near-term delta remov
servic growth resum new order demand
improv work partner waiv
build relationship difficult time
link full note
sunesi report financi includ net loss cash balanc
march enrol dose escal portion vecabrutinib
phase i/ ii trial continu initi respons asses asses
cohort expect remain skeptic
vecabrutinib find efficaci remain market perform
link full note
earli invest digital/onlin sale help off-set impact
execut better expect compani earli push
digit on-line sale last year help mitig impact
major product facil begin ramp capac slate
doubl visibl liquid ntm maxeon spin set
storag lift expect equinox offer
link full note
firework last week updat rel
unev financi broadli line expect manag reiter
expect final os data studi end june recent
financ meaning fortifi balanc sheet rais po assumpt
menin program increas dcf valuat outperform
link full note
weak pull guid lower visibl new ceo posit step
report weak w/ net new recur revenue margin cash flow
est management note slip deal delay cash collect though
improv april guid withdrawn recur revenue guid
estimate new ceo posit step take time organ new strategi
maintain market perform rate lower pt
link full note
oper result came slightli view fcfe surpris aggress
work cap reduct expect refrain offer guidanc
announc addit cost reduction/liquid preserv measur sbq/smt
market reel concentr g/auto exposur look color
initi near term market dynam tomorrow call
link full note
